Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Executive Summary
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
You may also be interested in...
Legal News: Teva V. FDA, Pay-For-Delay, Citizen Petitions, User Fee Scheme
US court tosses Teva suit seeking generic Restasis exclusivity. FTC loses appeal challenging Shire's citizen petitions, settles Solvay pay-for-delay case. DoJ resolves FCA case alleging company made deal to avoid paying FDA user fees for two NDAs.
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.